Results of the review
Eighteen RCTs with 3,045 participants (intervention = 1,387, control = 1,658) were included in the review.
The median Jadad score was 4 (range: 1 to 5). For the main outcome of PONV for the whole population, 8 RCTs demonstrated that dimenhydrinate was associated with a higher incidence of patients without emetic symptoms in the 'early' observation period (RB 1.21, 95% CI: 1.07, 1.35). Six trials found a significant benefit for PV for patients receiving dimenhydrinate versus placebo (RB 1.20, 95% CI: 1.03, 1.40). Two trials only reported PN and the results were not significant.
For the 'overall' first 48 hours post-operatively, 16 RCTs found a significant benefit for patients treated with dimenhydrinate versus placebo (RB 1.51, 95% CI: 1.27, 1.78). Fourteen RCTs found a significant benefit in favour of dimenhydrinate versus placebo for PV (RB 1.45, 95% CI: 1.22, 1.72), while 7 trials found a significant benefit in favour of dimenhydrinate versus placebo for PN (RB 1.32, 95% CI: 1.03, 1.70).
No major harm associated with the use of dimenhydrinate was reported by any of the studies, but owing to the sparse reporting of side-effects, no pooled statistical analysis was undertaken.
'Overall' first 48 hours post-operatively for the different subgroups.
For adults given a single application of dimenhydrinate (i.v. or i.m., 1 to 2 mg/kg), the pooled data from 3 RCTs gave a statistically-significant RB of 1.20 (95% CI: 1.01, 1.42) in favour of dimenhydrinate, versus placebo. A further 6 RCTs with a repetition (1 or 3 times 1.2 mg/kg rectal or i.v.) after the initial dose of 1 mg/kg gave a significant result in favour of dimenhydrinate versus placebo (RB 1.55, 95% CI: 1.05, 2.29). There was a non significant trend favouring the latter regimen.
For children, the pooled data from 3 RCTs demonstrated that a single i.v. or i.m. application of 0.5 to 2.2 mg/kg was as effective (RB 1.80, 95% CI: 1.31, 2.47) as a single rectal application of a dose of 2 to 3 mg/kg (RB 1.71, 95% CI: 1.16, 2.53).
